Using government data to understand the use and availability of medicines for hypertension and diabetes: lessons from Peru

References

• Lin X, Xu Y, Pan X, Xu J, Ding Y, Sun X, et al. Global, regional, and national burden and trend of diabetes in 195 countries and territories: an analysis from 1990 to 2025. Sci Rep 2020;10(1):1–11.
   PubMed Web of Science ®Google Scholar
• Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet 2021;398(10304):957–980.
   PubMed Web of Science ®Google Scholar
• Basu S, Yudkin JS, Kehlenbrink S, Davies JI, Wild SH, Lipska KJ, et al. Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis. Lancet Diabetes Endocrinol 2019;7(1):25–33.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global action plan for the prevention and control of NCDs 2013–2020. Geneva:WHO;2013.
   Google Scholar
• Emmerick ICM, Oliveira MA, Luiza VL, Azeredo TB, Bigdeli M. Access to medicines in Latin America and the Caribbean (LAC): a scoping study. BMJ Open 2013;3(5):e002224.
   PubMed Web of Science ®Google Scholar
• Moye-Holz D, van Dijk JP, Reijneveld SA, Hogerzeil HV. Policy approaches to improve availability and affordability of medicines in Mexico-an example of a middle income country. Glob Health 2017;13(1):53.
   PubMedGoogle Scholar
• Emmerick ICM, Luiza VL, Bastos Camacho LA, Vialle-Valentin C, Ross-Degnan D. Barriers in household access to medicines for chronic conditions in three Latin American countries. Int J Equity Health 2015;14(1):1–14.
   PubMedGoogle Scholar
• Vialle-Valentin CE, Serumaga B, Wagner AK, Ross-Degnan D. Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countries. Health Policy Plan 2015;30(8):1044–1052.
   PubMed Web of Science ®Google Scholar
• Husain MJ, Datta BK, Kostova D, Joseph KT, Asma S, Richter P, et al. Access to cardiovascular disease and hypertension medicines in developing countries: an analysis of essential medicine lists, price, availability, and affordability. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2020. https://doi.org/10.1161/JAHA.119.015302.
   Google Scholar
• Sm Van Mourik M, Cameron A, Ewen M, Laing RO. Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord. 2010;10:25.
   PubMed Web of Science ®Google Scholar
• Babar ZUD, Gammie T, Seyfoddin A, Hasan SS, Curley LE. Patient access to medicines in two countries with similar health systems and differing medicines policies: implications from a comprehensive literature review. Res Soc Adm Pharm. 2019;15(3):231–243.
   PubMed Web of Science ®Google Scholar
• Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, et al. Access to medicines from a health system perspective. Health Policy Plan. 2013;28:692–704.
   PubMed Web of Science ®Google Scholar
• Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet. 2017;389(10067):403.
   PubMedGoogle Scholar
• Management Sciences for Health. MDS-3: Managing Access to Medicines and Health Technologies. Arlington:Management Sciences for Health; 2012.p.1088.
   Google Scholar
• Ministerio de Salud del Perú. National drug policy. [Política nacional de medicamentos]. R.M. 1240–2004/MINSA Dec 24, 2004 p. 17.
   Google Scholar
• Mezones-Holguín E, Solis-Cóndor R, Benites-Zapata VA, Garnica-Pinazo G, Marquez-Bobadilla E, Tantaleán-Del-Águila M, et al. Institutional differences in the insufficient effective access to prescribed drugs in health care institutions in Peru: Analysis of the national survey of satisfaction of users of health services (ENSUSALUD 2014). [Diferencias institucionales en el insuficiente acceso efectivo a medicamentos prescritos en instituciones prestadoras de servicios de salud en Perú: análisis de la encuesta nacional de satisfacción de usaurios de los servicios e salud (ENSUSALUD 2017)]. 2016;33(2):205–14.
   Google Scholar
• Hodgkin D, Piazza M, Crisante M, Gallo C, Fiestas F. Availability of psychotropic medicines in Peruvian Ministry of Health facilities, 2011. [Disponibilidad de medicamentos psicotrópicos en establecimientos del Ministerio de Salud del Perú, 2011]. Rev Peru Med Exp Salud Publica. 2014;31(4):660–668.
   PubMedGoogle Scholar
• Tenorio-Mucha J, Lazo-Porras M, Hidalgo-Padilla L, Beran D, Ewen M. Prices, availability and affordability of insulin in public and private pharmacies in Peru. [Precios, disponibilidad y asequibilidad de insulina en farmacias públicas y privadas en Perú]. Rev Panam Salud Pública. 2019;43:1.
   Google Scholar
• Espinoza-Marchan H, Alvarez-Risco A, Solís-Tarazona Z, Villegas-Chiguala J, Zavaleta-Calderón A, Astuvilca-Cupe J, et al. Access to medicines in Seguro Integral de Salud (SIS) patients with diabetes mellitus and/or arterial hypertension in Peru. [Acceso a medicamentos en pacientes del Seguro Integral de Salud (SIS) con diabetes mellitus y/o hipertensión arterial en Perú]. Rev la OFIL. 2021;31(1):71–77.
   Google Scholar
• Cardenas MK, Miranda JJ, Beran D. Delivery of Type 2 diabetes care in low- and middle-income countries: lessons from Lima. Peru Diabet Med. 2016;33(6):752–760.
   PubMed Web of Science ®Google Scholar
• Robertson J, Macé C, Forte G, de Joncheere K, Beran D. Medicines availability for non-communicable diseases: the case for standardized monitoring. Global Health. 2015;11(18).
   Google Scholar
• Susalud | Inicio [Internet]. [cited 2022 Jul 10]. http://renipress.susalud.gob.pe:8080/wb-renipress/inicio.htm#
   Google Scholar
• Ministerio de salud. Module II: Estimation of needs and programming of medicines and supplies. [Modulo II: Estimación de necesidades y programación de medicamentos e insumos]. In: Processes of the comprehensive supply system for medicines and supplies in the Ministry of Health [Procesos del Sistema Integrado de Suministro de Medicamentos e Insumos en el Ministerio de Salud]. Lima-Perú.; 2006. p. 29.
   Google Scholar
• Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr. 2013;13:S38–44.
   PubMed Web of Science ®Google Scholar
• Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299–309.
   PubMed Web of Science ®Google Scholar
• Jandoc R, Burden AM, Mamdani M, Lévesque LE, Cadarette SM. Interrupted time series analysis in drug utilization research is increasing: Systematic review and recommendations. In: Journal of Clinical Epidemiology. 2015; 950–6.
   Google Scholar
• Ministerio de Salud del Perú. Clinical practice guideline for the diagnosis, treatment and management of diabetes mellitus type 2 in the primary level of care. [Guía de práctica clínica para el diagnóstico, tratamiento y control de la diabetes mellitus tipo 2 en el primer nivel de atención]. R.M. 719–2015/MINSA Perú; 2016 p. 66.
   Google Scholar
• Ministerio de Salud del Perú. Clinical practice guideline for the diagnosis, treatment and control of hypertensive disease. [Guía de práctica clínica para el diagnóstico, tratamiento y control de la enfermedad hipertensiva]. RM.031–2015/MINSA Perú; 2015 p. 25.
   Google Scholar
• Hsu JC, Ross-Degnan D, Wagner AK, Cheng C-L, Yang Y-HK, Zhang F, et al. Utilization of oral antidiabetic medications in Taiwan following strategies to promote access to medicines for chronic diseases in community pharmacies. J Pharm Policy Pract. 2015;8(1):1–9.
   PubMedGoogle Scholar
• Zafra-Tanaka JH, Najarro L, Tenorio-Mucha J, Lazo-Porras M, Bartra D, Bazán G, et al. COVID-19’s impact on type 1 diabetes management: A mixed-methods study exploring the Peruvian experience. Int J Health Plann Manage. 2022
   Google Scholar
• Ministerio de salud del Perú. Technical document: Nutritional consultation for the prevention and control of type 2 diabetes mellitus in young people, adults and the elderly. [Documento técnico: Consulta nutricional para la prevención y control de la diabetes mellitus tipo 2 de la persona joven, adultay adulta mayor]. RM 162–2015/MINSA 2015 p. 45.
   Google Scholar
• Ministerio de Salud del Perú. Clinical practice guidelines for the diagnosis, management and control of dyslipidemia, renal and ocular complications in people with type 2 diabetes mellitus. [Guía de práctica clínica para el diagnóstico, manejo y control de dislipidemia, complicaciones renales y oculares en personas con diabetes mellitus tipo2]. RM 039–2017/MINSA 2017 p. 64.
   Google Scholar
• Ministerio de Salud. Health directive for the comprehensive health care of people with noncommunicable diseases in the context of the COVID-19 pandemic. [Directiva sanitaria para el cuidado integral de la salud de las personas con enfermedades no transmisibles en el contexto de la pandemia por COVID-19]. RM 498–2020/MINSA Jul 15, 2020 p. 50.
   Google Scholar
• Neira-Sanchez E, Málaga G. Are the clinical practice guidelines for arterial hypertension and type 2 diabetes mellitus prepared by MINSA reliable? . [¿Son las guías de práctica clínica de hipertensión arterial y diabetes mellitus tipo 2 elaboradas por el MINSA, confiables?]. Rev Peru Med Exp Salud Publica. 2016;33(2).
   Google Scholar
• Atun R, Jaff S, Nishtar S, Knaul FM, Barreto ML, At Nyirenda M, et al. Improving responsiveness of health systems to non-communicable diseases. Lancet. 2013;381:690–697.
   PubMed Web of Science ®Google Scholar
• Ministerio de salud del Perú. Management of the integrated public supply system for pharmaceuticals, medical devices and medical devices-SISMED. [Gestión del sistema integrado de suministro público de productos farmacéuticos, dispositivos médicos y productos sanitarios-SISMED]. RM 116–2018/MINSA Diario Oficial El Peruano; 2018 p. 27.
   Google Scholar